title: Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
abstract: OBJECTIVE
  To assess the relative efficacy and tolerability of preservative-free latanoprost (T2345) compared with other prostaglandin analogues (PGA) for the treatment of open-angle glaucoma and ocular hypertension by adjusted indirect comparison meta-analysis.
  
  
  METHODS
  Randomized, controlled trials evaluating PGA for the treatment of open-angle glaucoma and ocular hypertension were identified by a systematic literature review in MEDLINE, EMBASE, and Cochrane Controlled Trials Register (up to December 2011) databases. The effect size for each treatment and heterogeneity were assessed by classical pairwise meta-analysis (direct comparisons). Adjusted indirect comparisons were performed by using Bucher method. The main endpoints were intraocular pressure (IOP) measured at 3 months and incidence of hyperemia.
  
  
  RESULTS
  Twenty-one studies were included in the meta-analysis. No statistically significant differences in IOP at 3 months were seen between T2345 and travoprost [preserved with benzalkonium chloride (BAK), polyquaternium-1 or sofzia], and other BAK-preserved PGA: bimatoprost 0.03%, bimatoprost 0.01%, or latanoprost. T2345 was statistically significantly superior to BAK-tafluprost (mean difference: 0.47 mm Hg, 95% confidence interval, [-1.52;-0.28]). The risk of hyperemia was statistically significantly lower with T2345 than with all the other PGA.
  
  
  CONCLUSIONS
  Indirect comparisons never found preservative-free latanoprost (T2345) to be statistically significantly inferior to the other PGA in terms of efficacy on IOP and showed statistically significant superiority over BAK-tafluprost. The risk of hyperemia was statistically significantly lower with T2345 than with all the other PGA.
authors.affiliation: *UMR CNRS 5558, Faculté de Médecine Laennec, Lyon ‡Ophthalmology Department, University of Lille, Lille, France †Ophthalmology Department, University Hospitals Leuven, Leuven, Belgium.
authors.forename: Michel
authors.initials: M
authors.lastname: Cucherat
authors.forename: Ingeborg
authors.initials: I
authors.lastname: Stalmans
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Rouland
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001548:Benzalkonium Compounds / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011108:Polymers / Q000009:adverse effects / Q000627:therapeutic use; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014065:Tonometry, Ocular; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D001548:Benzalkonium Compounds; D009883:Ophthalmic Solutions; D011108:Polymers; D011310:Preservatives, Pharmaceutical; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; C058655:polyquaternium 1